Ibrutinib provides favourable survival outcomes in patients with comorbidities versus established therapies-Reference-Cited by-同舟云学术

Ibrutinib provides favourable survival outcomes in patients with comorbidities versus established therapies

Published:2019-02-10 Issue:1 Volume:186 Page:175-180
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Burger Jan A.¹^ORCID,Cramer Paula²,Barr Paul M.³,Dilhuydy Marie‐Sarah⁴,Mato Anthony⁵,Byrd John C.⁶,Chang Stephen⁷,Graef Thorsten⁷,Lin Tony⁷,Tedeschi Alessandra⁸

Affiliation:

1. University of Texas MD Anderson Cancer Center Houston TX USA

2. German CLL Study Group University of Cologne Cologne Germany

3. University of Rochester Cancer Center Rochester NY USA

4. Centre Hospitalier Universitaire Bordeaux Bordeaux France

5. Memorial Sloan Kettering Cancer Center New York City NYUSA

6. The Ohio State University Columbus OH USA

7. Pharmacyclics LLC, an AbbVie Company Sunnyvale CA USA

8. Azienda Ospedaliera Niguarda Cà Granda Milan Italy

Funder

Janssen Research and Development

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.15784

Reference8 articles.

1. Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic model

2. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

3. Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

4. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

5. Frontline chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): final analysis of an international, randomized study of the German CLL Study Group (GCLLSG) (CLL10 Study);Eichhorst B.;Blood (56th ASH Annual Meeting ‐ Abstracts and Meeting Program),2014

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How Have Targeted Agents Changed the Treatment Landscape for Elderly Patients with CLL?;Current Oncology Reports;2022-11-05

2. Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?;Blood Advances;2021-12-17

3. What Is Fitness in the Era of Targeted Agents?;Clinical Lymphoma Myeloma and Leukemia;2021-12

4. A perspective on prognostic models in chronic lymphocytic leukemia in the era of targeted agents;Hematological Oncology;2021-10

5. Incorporating acalabrutinib, a selective next‐generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies;British Journal of Haematology;2020-11-20